Thank you, Chair.
I'd like to thank the four witnesses for staying with us so abidingly.
I'll continue where I left off. We were talking about genome editing. I did like the end of the minister's reply, when she said that if a problem arose, action would be taken. What worries the community is that we don't know how we're going to ensure that the database is complete and that proper monitoring is being done.
So you say you'll take action if there's an issue, but can you give us more details on the timeline? How often will consultations take place between industry and the committee, among other things? I'd like you to keep your answer brief.